ChemoCentryx to Host Virtual R&D Day on April 14, 2021
April 07 2021 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will
host a virtual R&D Day on Wednesday, April 14, 2021 beginning
at 12:30 p.m. ET. The event will feature a panel of key opinion
leaders, a testimonial from a patient living with ANCA-associated
vasculitis and members of the ChemoCentryx Management team. The
event will focus on the Company’s upcoming milestones and
developments in key pipeline programs.
Presenters:
- Thomas J.
Schall, Ph.D., President and Chief Executive Officer of
ChemoCentryx
- Tausif (“Tosh”)
Butt, Executive Vice President and Chief Operating Officer of
ChemoCentryx
- David Jayne, M.D., Director of the Vasculitis and Lupus
Service, Addenbrooke’s Hospital in Cambridge
- Peter A. Merkel,
M.D., MPH, Chief of Rheumatology and Professor of Medicine and
Epidemiology at the University of Pennsylvania
- Glen Massie,
Patient living with ANCA-associated vasculitis
Virtual R&D Day Information:
- Date: Wednesday, April 14,
2021
- Time: 12:30pm – 3:00pm ET
- Live webcast
link: https://wsw.com/webcast/cc/ccxi2/
Following completion of the live event, an archived webcast can
be accessed through the Investors section of the Company’s website
at www.ChemoCentryx.com, approximately two hours following the
event. The archived webcast will remain available on the Company’s
website for 60 days.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications for inflammatory and autoimmune diseases and cancer.
ChemoCentryx targets the chemokine and chemoattractant systems to
discover, develop and commercialize orally-administered therapies.
ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully
completed a pivotal Phase III trial in ANCA-associated vasculitis
and a New Drug Application is under review by the U.S. Food and
Drug Administration. Avacopan is also in late stage clinical
development for the treatment of severe Hidradenitis Suppurativa
and C3 glomerulopathy (C3G).
ChemoCentryx also has early stage drug candidates that target
chemoattractant receptors in other inflammatory and autoimmune
diseases and in cancer.
Contacts:Susan M. KanayaExecutive Vice
President,Chief Financial and Administrative
Officerinvestor@chemocentryx.com
Media:Stephanie
Tomei408.234.1279media@chemocentryx.com
Investors:Burns McClellan, Inc.Lee
Roth212.213.0006lroth@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Sep 2023 to Sep 2024